COMMUNIQUÉ DE PRESSE publié le 05/12/2023 à 16:00, il y a 1 année 11 mois First Light Diagnostics Receives FDA Clearance for its Rapid B. anthracis Toxin Test on the MultiPath Analyzer First Light Diagnostics receives FDA clearance for its SensiTox B. anthracis Toxin Test, a 20-minute, sensitive immunofluorescence assay for early detection of inhalation anthrax, marking a significant advancement in biodefense and public health FDA Clearance First Light Diagnostics SensiTox B. Anthracis Toxin Test Inhalation Anthrax Biodefense
Publié le 04/12/2025 à 18:14, il y a 12 heures 54 minutes Résiliation d'une convention conclue entre actionnaires
Publié le 04/12/2025 à 18:00, il y a 13 heures 9 minutes Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Publié le 04/12/2025 à 18:00, il y a 13 heures 9 minutes Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Publié le 04/12/2025 à 17:45, il y a 13 heures 24 minutes Informations relatives au nombre total de droits de vote et d’actions
Publié le 04/12/2025 à 17:45, il y a 13 heures 24 minutes MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Publié le 05/12/2025 à 02:35, il y a 4 heures 34 minutes Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Publié le 05/12/2025 à 01:00, il y a 6 heures 9 minutes BEACN Closes First Tranche of Non-Brokered Private Placement
Publié le 04/12/2025 à 23:05, il y a 8 heures 4 minutes BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Publié le 04/12/2025 à 23:00, il y a 8 heures 9 minutes NXT Energy Solutions Completes Data Acquisition for SFD Survey
Publié le 05/12/2025 à 03:30, il y a 3 heures 39 minutes CGTN: What makes cooperation between China and France a two-way success
Publié le 04/12/2025 à 23:50, il y a 7 heures 18 minutes EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Publié le 04/12/2025 à 20:25, il y a 10 heures 44 minutes Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Publié le 04/12/2025 à 20:15, il y a 10 heures 54 minutes Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Publié le 04/12/2025 à 19:10, il y a 11 heures 59 minutes SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance